Plain-English translation of NCT07046923 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Read our Carcinoma, Non-Small-Cell Lung research guide โPhase 1 โ Testing in a small group (usually 20โ80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This trial is testing a new medication called , which is an antibody drug designed to find and attack cancer cells. Researchers want to learn if this treatment is safe, how well it works, and how your body processes it. You would receive the medication through an IV (intravenous) infusion, sometimes combined with other cancer drugs depending on which group you join.
Many people with advanced cancers like lung cancer, breast cancer, and endometrial cancer have limited treatment options, especially after standard therapies stop working. This medication targets a specific protein on cancer cells, offering hope for a new way to fight these cancers.
You would receive the medication through an IV infusion at a hospital or clinic, with doses and combinations varying depending on which study group you're assigned to. Some participants receive the new medication alone, while others receive it combined with established cancer drugs like or chemotherapy. Your participation could last up to 4 years, involving regular clinic visits for infusions, blood tests, imaging scans, and monitoring of side effects.
AI-generated summary from trial data ยท Jun 24, 2026 ยท Not medical advice
United States